Carbonylamino Pyrrolopyrazole compounds of formula I, compositions including these compounds and methods of their use are provided. Preferred compounds of formula I have activity as protein kinase inhibitors, including as inhibitors of PAK4.
2-hydroxyamide derivatives are produced based on the kineticresolution of racemic 2-hydroxyamides with a diphenylacetyl component and (R)-benzotetramisole ((R)-BTM), a chiral acyl-transfer catalyst, via asymmetric esterification and acylation. It was revealed that a tertiary amide can be used with this novel protocol to achieve high selectivity (22 examples; s-value reaching over 250). The resulting chiral
Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I,
and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
(EN) Carbonylamino Pyrrolopyrazole compounds of formula (I), compositions including these compounds and methods of their use are provided. Preferred compounds of formula (I) have activity as protein kinase inhibitors, including as inhibitors of PAK4.(FR) La présente invention concerne des composés de carbonylamino-pyrrolopyrazole de formule I, des compositions comprenant ces composés et des procédés pour leur utilisation. Les composés de formule I préférés ont une activité en tant qu'inhibiteurs de protéine kinase, y compris en tant qu'inhibiteurs de PAK4.